CorVivo

Executive Summary

CorVivo (operating as CorMatrix Cardiovascular) is a private, clinical-stage medical device company based in San Diego, CA, dedicated to revolutionizing cardiovascular repair through its proprietary biomaterial platform. The company leverages an extracellular matrix (ECM) technology that harnesses the body's innate healing mechanisms to regenerate cardiac and vascular tissues, offering a potential alternative to synthetic grafts or permanent implants. With a focus on addressing significant unmet needs in cardiac reconstruction, peripheral vascular repair, and pediatric congenital heart defects, CorVivo's platform has shown promise in preclinical and early clinical studies by promoting natural tissue remodeling and reducing complications such as stenosis or calcification. The company aims to become a global leader in regenerative cardiovascular solutions, positioning itself at the intersection of advanced biomaterials and tissue engineering. CorVivo's development pipeline includes several products targeting both FDA-cleared and investigational indications. The company has already received 510(k) clearance for certain surgical patches, and it is now advancing toward pivotal clinical trials for its lead product candidates in larger indications. Recent progress includes the initiation of a multi-center study for its vascular graft in peripheral artery disease, with early safety and efficacy data expected. Commercialization efforts are supported by existing revenue from cleared products, while the pipeline seeks to expand into high-growth markets. Key upcoming milestones include FDA feedback on a planned investigational device exemption (IDE) submission and potential breakthrough device designation for a pediatric cardiac indication.

Upcoming Catalysts (preview)

• Q3 2026FDA Breakthrough Device Designation for Pediatric Cardiac ECM Patch70% success
• Q4 2026Interim Data Readout from Pivotal Trial of Vascular Graft in Peripheral Artery Disease60% success
• Q1 2027Strategic Partnership with Major Cardiovascular Device Company for Global Distribution50% success